Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients with MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis. Clin Gastroenterol Hepatol. 2024 Jul 20.
PMID: 39038768
The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis.
The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis. J Med Econ. 2024 Jan-Dec; 27(1):919-930.
PMID: 38953706
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study.
Cost burden of cirrhosis and liver disease progression in metabolic dysfunction-associated steatohepatitis: A US cohort study. J Manag Care Spec Pharm. 2024 Sep; 30(9):929-941.
PMID: 38845444
Envisioning how to advance the MASH field.
Envisioning how to advance the MASH field. Nat Rev Gastroenterol Hepatol. 2024 Oct; 21(10):726-738.
PMID: 38834817
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024 Apr; 136(3):229-245.
PMID: 38465573
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests.
Prevalence of Nonalcoholic Steatohepatitis and Associated Fibrosis Stages Among US Adults Using Imaging-Based vs Biomarker-Based Noninvasive Tests. J Health Econ Outcomes Res. 2024; 11(1):32-43.
PMID: 38370007
Macrophage RAGE activation is proinflammatory in NASH.
Macrophage RAGE activation is proinflammatory in NASH. JCI Insight. 2024 Feb 08; 9(3).
PMID: 38175729
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 02 08; 390(6):497-509.
PMID: 38324483
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.
Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease. Nat Microbiol. 2023 Nov; 8(11):2033-2049.
PMID: 37845315
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis.
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis. Viruses. 2023 09 29; 15(10).
PMID: 37896803